淚囊炎市場- 治療（手術、藥物{抗生素}）、適應症（慢性淚囊炎、急性淚囊炎、先天性淚囊炎）、最終用戶（機構銷售、零售） - 全球預測（2024 - 2032 ）

由於人們對淚囊炎的認知和診斷不斷提高，以及易患眼部感染的老年人口不斷增加，全球淚囊炎市場在 2024 年至 2032 年間的複合年成長率將超過 5.3%。複雜的診斷工具和微創手術技術等創新徹底改變了治療方法，帶來更準確的診斷和有效的治療。這些技術進步縮短了患者的復原時間並改善了治療結果。舉個例子，2023 年 5 月，博士倫和 Novaliq 宣布 FDA 批准 MIEBO(TM)（全氟己基辛烷眼用溶液）用於治療乾眼症。 MIEBO 是第一個獲得 FDA 批准的針對淚液蒸發的眼藥水，基於關鍵 3 期試驗的成功結果。

高解析度內視鏡等增強成像技術可以更好地可視化淚囊和導管系統，有助於對淚囊炎進行精確干預。此外，先進治療程序的開發有助於提高效率和病人安全，從而促進市場成長。

整個淚囊炎市場根據治療、適應症、最終用戶和地區進行細分。

由於認知和診斷率不斷提高，到 2032 年，藥物領域將呈現強勁的複合年成長率。醫療保健服務的改善導致更多患者尋求治療，從而刺激了對有效藥物選擇的需求。醫學研究的進步導致新藥物配方和療法的開發。慢性病的盛行率不斷上升和人口老化導致淚囊炎的盛行率更高。隨著患者和醫療保健提供者尋求治療淚囊炎的創新解決方案，對藥物的需求將會增加。

由於急診症狀的發生率較高，到 2032 年，急性淚囊炎細分市場將佔據重要的市場佔有率。急性淚囊炎的特徵是淚囊突然發炎感染，需要立即就醫。細菌感染激增和環境觸發因素等因素導致病例增加。此外，診斷能力的提高使得更多病例得以及早發現。患者意識的提高和積極主動的醫療保健實踐推動了對有效管理解決方案的需求，以確保快速緩解急性症狀並減少潛在的併發症。

由於人們對該疾病的認知不斷提高和早期診斷，歐洲淚囊炎市場從 2024 年到 2032 年將呈現強勁的複合年成長率。公共衛生措施和教育活動正在導致更多的人尋求及時治療。歐洲先進的醫療保健基礎設施促進了專業護理的取得，擴大了需求。該地區人口老化，更容易受到眼部感染，這增加了對有效淚囊炎管理解決方案的需求。這些因素共同促成了正面的市場前景。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性和先天性淚囊炎的盛行率不斷增加
    • 對先進眼科治療方案的認知不斷增強
    • 人口老化加劇
    • 先進的診斷技術可及時診斷淚囊炎
  • 產業陷阱與挑戰
    • 存在嚴格的法規
    • 副作用風險高
• 成長潛力分析
• 監管環境
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按處理方式，2021 - 2032

• 主要趨勢
• 手術
• 藥物
  • 抗生素
  • 其他藥物

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 慢性淚囊炎
• 急性淚囊炎
• 先天性淚囊炎

第 7 章：市場估計與預測：按配銷通路，2021 - 2032

• 主要趨勢
• 機構銷售
• 零售額

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc. (Allergan)
• Alcon Inc.
• Aurolab
• Bausch Health Companies Inc.
• Bayer AG
• BVM Medical Limited
• F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• FCI Ophthalmics
• Gunther Weiss Scientific Glassblowing Co., Inc.
• Heart Medical Europe BV
• Kaneka Corporation
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.

Global Dacryocystitis Market will record over 5.3% CAGR between 2024 and 2032, catapulted by increasing awareness & diagnosis of the condition, and a rising geriatric population susceptible to eye infections. Innovations such as sophisticated diagnostic tools and minimally invasive surgical techniques have revolutionized treatment approaches, leading to more accurate diagnoses and effective therapies. These technological advancements cut patient recovery time and improve treatment outcomes. Quoting an instance, in May 2023, Bausch + Lomb and Novaliq announced FDA approval of MIEBO(TM) (perfluorohexyloctane ophthalmic solution) for treating dry eye disease. MIEBO is the first FDA-approved eye drop targeting tear evaporation, based on successful results from pivotal Phase 3 trials.

Enhanced imaging technologies, such as high-resolution endoscopy, allow for better visualization of the lacrimal sac and duct systems, facilitating precise interventions for dacryocystitis. Additionally, the development of advanced therapeutic procedures contributes to augmenting efficiency and patient safety, ushering the market growth.

The overall dacryocystitis market is segmented based on treatment, indication, end user, and region.

The medication segment will exhibit a robust CAGR through 2032, because of increasing awareness and diagnosis rates. Improved healthcare access is leading to more patients seeking treatment, spurring the need for effective medication options. Advancements in medical research are resulting in the development of new drug formulations and therapies. The growing prevalence of chronic conditions and an aging population lead to higher prevalence of dacryocystitis. As patients and healthcare providers seek innovative solutions for managing dacryocystitis, the demand for medications will increase.

The acute dacryocystitis segment will achieve a significant market share by 2032, owing to the higher incidence of rapid-onset symptoms. Acute dacryocystitis, characterized by sudden inflammation and infection of the lacrimal sac, requires prompt medical attention. Factors such as an upsurge in bacterial infections and environmental triggers leads to increased cases. Additionally, improved diagnostic capabilities have led to more cases being identified early. Increased patient awareness and proactive healthcare practices drive demand for effective management solutions, ensuring rapid relief from acute symptoms and reducing potential complications.

Europe dacryocystitis market will show a strong CAGR from 2024 to 2032, due to rising awareness and early diagnosis of the condition. The public health initiatives and educational campaigns are leading to more individuals seeking timely treatment. Europe's advanced healthcare infrastructure facilitates access to specialized care, amplifying demand. The region's aging population, which is more susceptible to eye infections, is boosting the need for effective dacryocystitis management solutions. These factors collectively contribute to a positive market outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and congenital dacryocystitis
    • 3.2.1.2 Growing awareness towards advanced ophthalmic treatment options
    • 3.2.1.3 Increasing aging population
    • 3.2.1.4 Availability of advanced diagnostic techniques to timely diagnose dacryocystitis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Presence of stringent regulations
    • 3.2.2.2 High risk of side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Surgery
• 5.3 Medication
  • 5.3.1 Antibiotics
  • 5.3.2 Other medications

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic dacryocystitis
• 6.3 Acute dacryocystitis
• 6.4 Congenital dacryocystitis

Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Institutional sales
• 7.3 Retail sales

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc. (Allergan)
• 9.2 Alcon Inc.
• 9.3 Aurolab
• 9.4 Bausch Health Companies Inc.
• 9.5 Bayer AG
• 9.6 BVM Medical Limited
• 9.7 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• 9.8 FCI Ophthalmics
• 9.9 Gunther Weiss Scientific Glassblowing Co., Inc.
• 9.10 Heart Medical Europe BV
• 9.11 Kaneka Corporation
• 9.12 Merck & Co., Inc.
• 9.13 Novartis AG
• 9.14 Pfizer Inc.
• 9.15 Regeneron Pharmaceuticals Inc.